The global systemic oral azoles market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of fungal infections and the growing awareness about the benefits of systemic oral azoles in treating these infections.
The global systemic oral azoles market is segmented on the basis of type, application, and region. On the basis of type, it is classified into fluconazole, itraconazole, and posaconazole. Fluconazole accounted for a major share in 2017 owing to its wide range of applications such as treatment for candidiasis (gastrointestinal tract or genitourinary tract) and prevention against invasive candidiasis in high-risk patients undergoing chemotherapy or bone marrow transplantation. Itraconazole was used as an antifungal agent for treatment against various types of fungal infections such as blastomycosis; histoplasmosis; coccidioidomycosis; cryptococcosis; chromoblastomycosis; sporotrichosis; paracoccidioidomycoses (South American blastomycoses); penicilliosis (Asian blastomycoses); sporotrichoid dermatitis/cutaneous sporotrichosis/sporotrichia rubra verrucosa erythematosus/sporotrichia rubra pilaris/sporothrix schenckii infection (North American blastomyces). Posaconazole was used as an antifungal agent for treatment against various types of fungal infections such as candidaemia (bloodstream infection), invasive candidiasis in high-risk patients undergoing chemotherapy or bone marrow transplantation, chronic mucocutaneous candidiasis with extensive involvement including skin lesions that are resistant to topical therapy with other agents like ketoconazole or clotrimoxozone), chronic mucocutaneous candidiasis with extensive involvement including skin lesions that are resistant to topical therapy with other agents like ketoconazole or clotrimoxozone). On the basis on application it is classified into gastrointestinal Candida Infections and genitourinary tract Candida Infections. Gastrointestinal Candida Infections accounted for a major share owing to its wide range applications such as treatment for gastrointestinal Candida Infection caused by fluconizolae which includes esophageal thrush caused by yeast overgrowth due to use antibiotics which can cause yeast overgrowth leading up esophagitis due ot thrush causing inflammation leading up esophagitis due ot thrush causing inflammation leading up esophagitis due ot thrush causing inflammation leading up esophagitis due ot thrush causing inflammation leading up esophagitis due ot thrush causing inflammation leading up esophagitis due ot thrush caused by yeast overgrowth from use antibiotics which can cause yeast overgrowth leading upto stomach ulcers caused by Thrush because stomach acid kills off good bacteria but not bad bacteria so there's more room left open where bad bacteria can grow so you get more bad bacteria than good ones so you get more bad diseases because there's less good ones left alive then when you have too many bad ones they start fighting each other so they're all fighting each other insteadof fighting together against your body then when they fight each other they release toxins that make your body sicker than if they were just working together) Genitourinary tract Candida Infections accounted for a major share owing mainlyto its wide range applications such as treatment for genitourinary tract Candida Infection caused by fluconizolae which includes vulvovaginits associated with vaginal discharge characterizedby vulvar pruritus erythema edema burning dysuria vaginal dischargeand vulvar pruritus erythema edema burning dysuria vaginal dischargeand vulvar pruritus erythema edema burning dysuria vaginal dischargeand vulvar pruritus erythema edema burning dysuria vaginal dischargeand vulvar pruritus erythema edema burning dysuria vaginal dischargeand vulvar pruritus erythema edema burning dysuria vaginal discharge). On the basis on region it is classified into North America, Latin America, Europe Asia Pacific Middle East & Africa.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of fungal infections is a major factor driving the growth of the systemic oral azoles market.
- The increasing number of patients with diabetes mellitus is a major factor driving the growth of the systemic oral azoles market.
- The increasing number of patients with HIV/AIDS is a major factor driving the growth of the systemic oral azoles market.
- Increasing awareness about fungal infections and their treatment options among physicians and patients is expected to drive demand for systemic oral azoles in future years.
- Increasing incidence rates for chronic diseases such as diabetes mellitus, HIV/AIDS, and cancer are expected to drive demand for systemic oral azoles in future years.
Industry Growth Insights published a new data on “Systemic Oral Azoles Market”. The research report is titled “Systemic Oral Azoles Market research by Types (Fluconazole, Itraconazole, Posaconazole), By Applications (Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other), By Players/Companies Novartis AG, Pfizer, Inc, Sanofi-Aventis, Merck & Co., Inc, Enzon Pharmaceuticals, Inc, Bayer AG, Astellas Pharma, Inc, GlaxoSmithKline plc, Abbott”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Oral Azoles Market Research Report
By Type
Fluconazole, Itraconazole, Posaconazole
By Application
Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other
By Companies
Novartis AG, Pfizer, Inc, Sanofi-Aventis, Merck & Co., Inc, Enzon Pharmaceuticals, Inc, Bayer AG, Astellas Pharma, Inc, GlaxoSmithKline plc, Abbott
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Oral Azoles Market Report Segments:
The global Systemic Oral Azoles market is segmented on the basis of:
Types
Fluconazole, Itraconazole, Posaconazole
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Pfizer, Inc
- Sanofi-Aventis
- Merck & Co., Inc
- Enzon Pharmaceuticals, Inc
- Bayer AG
- Astellas Pharma, Inc
- GlaxoSmithKline plc
- Abbott
Highlights of The Systemic Oral Azoles Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fluconazole
- Itraconazole
- Posaconazole
- By Application:
- Gastrointestinal Candidiasis
- Genitourinary Tract Candidiasis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Oral Azoles Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic oral azoles are a class of medications that work by stopping the growth of fungi. These medications are often used to treat fungal infections, such as thrush or candida. Systemic oral azoles can also be used to treat other conditions, such as athlete's foot or jock itch.
Some of the key players operating in the systemic oral azoles market are Novartis AG, Pfizer, Inc, Sanofi-Aventis, Merck & Co., Inc, Enzon Pharmaceuticals, Inc, Bayer AG, Astellas Pharma, Inc, GlaxoSmithKline plc, Abbott.
The systemic oral azoles market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Systemic Oral Azoles Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Systemic Oral Azoles Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Systemic Oral Azoles Market - Supply Chain
4.5. Global Systemic Oral Azoles Market Forecast
4.5.1. Systemic Oral Azoles Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Systemic Oral Azoles Market Size (000 Units) and Y-o-Y Growth
4.5.3. Systemic Oral Azoles Market Absolute $ Opportunity
5. Global Systemic Oral Azoles Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Systemic Oral Azoles Market Size and Volume Forecast by Type
5.3.1. Fluconazole
5.3.2. Itraconazole
5.3.3. Posaconazole
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Systemic Oral Azoles Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Systemic Oral Azoles Market Size and Volume Forecast by Application
6.3.1. Gastrointestinal Candidiasis
6.3.2. Genitourinary Tract Candidiasis
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Systemic Oral Azoles Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Systemic Oral Azoles Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Systemic Oral Azoles Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Systemic Oral Azoles Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Systemic Oral Azoles Demand Share Forecast, 2019-2026
9. North America Systemic Oral Azoles Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Systemic Oral Azoles Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Systemic Oral Azoles Market Size and Volume Forecast by Application
9.4.1. Gastrointestinal Candidiasis
9.4.2. Genitourinary Tract Candidiasis
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Systemic Oral Azoles Market Size and Volume Forecast by Type
9.7.1. Fluconazole
9.7.2. Itraconazole
9.7.3. Posaconazole
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Systemic Oral Azoles Demand Share Forecast, 2019-2026
10. Latin America Systemic Oral Azoles Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Systemic Oral Azoles Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Systemic Oral Azoles Market Size and Volume Forecast by Application
10.4.1. Gastrointestinal Candidiasis
10.4.2. Genitourinary Tract Candidiasis
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Systemic Oral Azoles Market Size and Volume Forecast by Type
10.7.1. Fluconazole
10.7.2. Itraconazole
10.7.3. Posaconazole
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Systemic Oral Azoles Demand Share Forecast, 2019-2026
11. Europe Systemic Oral Azoles Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Systemic Oral Azoles Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Systemic Oral Azoles Market Size and Volume Forecast by Application
11.4.1. Gastrointestinal Candidiasis
11.4.2. Genitourinary Tract Candidiasis
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Systemic Oral Azoles Market Size and Volume Forecast by Type
11.7.1. Fluconazole
11.7.2. Itraconazole
11.7.3. Posaconazole
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o- Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Systemic Oral Azoles Demand Share, 2019-2026
12. Asia Pacific Systemic Oral Azoles Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Systemic Oral Azoles Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Systemic Oral Azoles Market Size and Volume Forecast by Application
12.4.1. Gastrointestinal Candidiasis
12.4.2. Genitourinary Tract Candidiasis
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Systemic Oral Azoles Market Size and Volume Forecast by Type
12.7.1. Fluconazole
12.7.2. Itraconazole
12.7.3. Posaconazole
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Systemic Oral Azoles Demand Share, 2019-2026
13. Middle East & Africa Systemic Oral Azoles Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Systemic Oral Azoles Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Systemic Oral Azoles Market Size and Volume Forecast by Application
13.4.1. Gastrointestinal Candidiasis
13.4.2. Genitourinary Tract Candidiasis
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Systemic Oral Azoles Market Size and Volume Forecast by Type
13.7.1. Fluconazole
13.7.2. Itraconazole
13.7.3. Posaconazole
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Systemic Oral Azoles Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Systemic Oral Azoles Market: Market Share Analysis
14.2. Systemic Oral Azoles Distributors and Customers
14.3. Systemic Oral Azoles Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer, Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi-Aventis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck & Co., Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Enzon Pharmaceuticals, Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer AG
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas Pharma, Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline plc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Abbott
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
